- Article
Canadian Institutes of Health [...]
June 2007 - 6 articles
Canadian Institutes of Health [...]
Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with sev...
Questions: (1) With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (CLL)? (2) What t...
Recommendation 1: Management of patients with glioblastoma multiforme (GBM) should be highly individualized and should take a multidisciplinary approach involving neuro-oncology, neurosurgery, radiation oncology, and pathology, to optimize treatment...
In medicine, assigning priorities for original ideas and for first implementation of a new type of treatment or technology—radium afterloading, for example—is often difficult. This situation is certainly true for radium therapy, with conflicting clai...
The Editorial Board is pleased to announce that Current Oncology is now included in the U.S. National Library of Medicine’s PubMed search engine. [...]